Clinical trial
S9926 Temozolomide in Patients With Unresectable/Metastatic Gastrointestinal…
NCT00005597 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00005597 |
|---|---|
| Title | S9926 Temozolomide in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors |
| Official title | Phase II Study of Temozolomide in Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastrointestinal Stromal Tumor |
| Intervention type | Drug |
| Interventions | temozolomide |
| Enrollment | 25 |
| Start date | Apr 1, 2000 |
| Primary completion | Oct 1, 2005 |
| Completion | Oct 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 3, 2013 |
| Countries | United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: